基于肺与大肠相表里理论探讨肠道菌群与肺癌免疫治疗  

Regulation between Intestinal Flora and Lung Cancer Immunotherapy Based on Relationship between Lung and Intestine

作　　者：刘瑶[1] 杨蕴[2] 田建辉[1,2] LIU Yao;YANG Yun;TIAN Jianhui(Cancer Institute of Chinese Medicine,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200241,China;Tumor Clinical Medical Center,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200071,China)

机构地区：[1]上海中医药大学附属市中医医院肿瘤研究所,上海200241 [2]上海中医药大学附属市中医医院肿瘤临床医学中心,上海200071

出　　处：《辽宁中医杂志》2025年第3期1-4,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金面上项目(81973517、82174245);上海市炎癌转化病证生物学前沿研究基地项目(2021科技03-12);上海市中医医院未来计划科技发展项目(WL-HBRC-2021001K);上海市卫生健康领军人才项目(2022LJ014)。

摘　　要：肠道菌群,是人体肠道的正常微生物,其能合成多种人体生长发育必需的维生素、必需氨基酸等营养物质,并参与糖类和蛋白质的代谢,对维持人体健康有着重要作用。“肺-肠轴”理论证实了肠道菌群失衡及其产生的有害代谢产物可以通过血液或者淋巴等途径影响肺癌的发生发展,甚至临床治疗效果。这与中医理论“肺与大肠相表里”高度契合。基于此,文章探讨了调控肠道菌群介导的肺癌免疫治疗研究进展,有望为提高免疫治疗疗效提供新思路。The gut microbiome is a normal microorganism in the human gut that synthesizes a variety of essential nutrients such as vitamins and amino acids for human growth and development,and participates in the metabolism of sugars and proteins,playing an important role in maintaining human health.The theory of the“lung-gut axis”confirms that the imbalance of the gut microbiome and the deleterious metabolites it produces can affect the occurrence and development of lung cancer,and even the effectiveness of clinical treatment,through blood or lymphatic pathways.Based on this,this review explored the research progress of immunotherapy for lung cancer mediated by regulating gut microbiota,which was expected to provide new ideas for improving the efficacy of immunotherapy.

关 键 词：肠道菌群 肺与大肠相表里 肺癌 免疫治疗 肺肠轴 

分 类 号：R273[医药卫生—中西医结合]